Legislation2 days ago
50
To authorize implementation grants to community-based nonprofits to operate one-stop reentry centers.
HR8548Rep. Kamlager-Dove, Sydney [D-CA-37] (D-CA)
introduced
HR8205119th CongressWALLET
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Sponsored By: Representative Rep. Quigley, Mike [D-IL-5]
Introduced
Summary
Extends the ALS Act authorization through 2031 and would tie grant renewals to clinical trial enrollment data while strengthening FDA planning and independent review to speed therapy development for ALS and related rare neurodegenerative diseases.
Show full summary
- Families and patients: Would aim to keep funding and program support available through 2031 and push for faster, more transparent trial enrollment information that could clarify when later-stage studies are ready to enroll patients.
- Researchers and drug sponsors: Would require sponsors to share interim clinical trial data and let grant reviewers assess enrollment status when considering renewals, and it clarifies that combined phase 2/3 and planned phase 3 trials count as phase 3 for ALS purposes.
- FDA and oversight bodies: Would require the FDA Commissioner to publish a five-year action plan within one year that covers program and regulatory priorities across rare neurodegenerative diseases, and it would require a Government Accountability Office report within four years analyzing data called for in the ALS Act.
Your PRIA Score
Score Hidden
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Extend ALS research grants authorization
If enacted, the bill would extend the ALS Act's grant authorization by replacing "2026" with "2031." This would keep the program's grant authority in effect through 2031. The change would not itself appropriate new funds.
New FDA plan and GAO report
If enacted, the bill would require the FDA Commissioner to publish, within one year, an updated five-year action plan on the FDA website. The plan would list actions, resources needed, and approaches to coordinate with non-ALS rare neurodegenerative disease communities, and would describe the June 23, 2022 action plan and actions taken. The bill would also require the Comptroller General to deliver a GAO report to two congressional committees within four years, containing the analyses and data described in section 6 of the ALS Act.
New trial data and enrollment checks
If enacted, the bill would require the HHS Secretary to assess patient enrollment in clinical trials when reviewing renewal applications for grants tied to investigational drugs. The Secretary would request interim clinical trial data from drug sponsors to support that assessment. The bill would also treat phase 2/3 combined trials and planned phase 3 trials not yet enrolling as "phase 3" for program purposes.
Free Policy Watch
You just read the policy. Now see what it costs you.
Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.
Pick a topic to get started
Sponsors & CoSponsors
Sponsor
Rep. Quigley, Mike [D-IL-5]
IL • D
Cosponsors
Rep. Calvert, Ken [R-CA-41]
CA • R
Sponsored 4/6/2026
Rep. Fitzpatrick, Brian K. [R-PA-1]
PA • R
Sponsored 4/9/2026
Rep. Schakowsky, Janice D. [D-IL-9]
IL • D
Sponsored 4/9/2026
McCaul
TX • R
Sponsored 4/9/2026
Garbarino
NY • R
Sponsored 4/16/2026
Rep. Auchincloss, Jake [D-MA-4]
MA • D
Sponsored 4/9/2026
DesJarlais
TN • R
Sponsored 4/9/2026
Craig
MN • D
Sponsored 4/9/2026
Valadao
CA • R
Sponsored 4/14/2026
Rep. Crow, Jason [D-CO-6]
CO • D
Sponsored 4/14/2026
Thompson (PA)
PA • R
Sponsored 4/14/2026
Rep. Moore, Gwen [D-WI-4]
WI • D
Sponsored 4/14/2026
Rep. Hurd, Jeff [R-CO-3]
CO • R
Sponsored 4/14/2026
Rep. Schneider, Bradley Scott [D-IL-10]
IL • D
Sponsored 4/14/2026
Rep. Joyce, David P. [R-OH-14]
OH • R
Sponsored 4/15/2026
Rep. Veasey, Marc A. [D-TX-33]
TX • D
Sponsored 4/15/2026
Salazar
FL • R
Sponsored 4/15/2026
Rep. Bonamici, Suzanne [D-OR-1]
OR • D
Sponsored 4/15/2026
Bilirakis
FL • R
Sponsored 4/16/2026
Rep. Sherman, Brad [D-CA-32]
CA • D
Sponsored 4/16/2026
Rep. Lynch, Stephen F. [D-MA-8]
MA • D
Sponsored 4/16/2026
Rep. Bacon, Don [R-NE-2]
NE • R
Sponsored 4/20/2026
Rep. Cohen, Steve [D-TN-9]
TN • D
Sponsored 4/20/2026
Sessions
TX • R
Sponsored 4/20/2026
Rep. Smith, Adam [D-WA-9]
WA • D
Sponsored 4/20/2026
Obernolte
CA • R
Sponsored 4/20/2026
Rep. Dean, Madeleine [D-PA-4]
PA • D
Sponsored 4/20/2026
Cole
OK • R
Sponsored 4/20/2026
Rep. Foushee, Valerie P. [D-NC-4]
NC • D
Sponsored 4/20/2026
Rep. Sewell, Terri A. [D-AL-7]
AL • D
Sponsored 4/21/2026
Rutherford
FL • R
Sponsored 4/21/2026
Wilson (SC)
SC • R
Sponsored 4/22/2026
Rep. Davis, Danny K. [D-IL-7]
IL • D
Sponsored 4/22/2026
Aderholt
AL • R
Sponsored 4/23/2026
Rep. Torres, Ritchie [D-NY-15]
NY • D
Sponsored 4/23/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in